Governance in the biotechnology industry tends to be discussed in the language of constraint. Compliance obligations. Fiduciary duties. Risk management frameworks. The board as a check on management rather than a force that shapes what management is able to attempt. Leen Kawas has spent her career working in and around governance structures that she regards as something more interesting than that, as argued here: as conditions that either enable or suppress the kind of scientific ambition that produces therapies capable of changing patient outcomes. Her experience across multiple boardrooms, as a founder-CEO who built and led a publicly listed biotech, and as a board member for companies developing solutions in epigenetics, reproductive health, and the infant microbiome, has given her a specific view of what distinguishes governance that accelerates innovation from governance that merely supervises it.

Kawas came to the United States from Jordan in 2008 to pursue doctoral research in molecular pharmacology, and co-founded what became Athira Pharma in 2014. She served as CEO through a September 2020 IPO that raised over $400 million, making her one of only 22 women founders in the US to have led a company to a public offering at that time, and the first woman in Washington State to do so in more than two decades. The governance architecture she operated within during that period, including her concurrent role on the company’s board of directors, was not incidental to Athira’s trajectory. It shaped which clinical programmes were advanced, which partnerships were pursued, and how the company communicated its scientific thesis to the investor community.

What Diverse Governance Actually Delivers

The argument of Leen Kawas on governance as a catalyst is direct about the link between board composition and the quality of strategic decision-making in biotech. She has pointed to research demonstrating that companies with diverse leadership teams generate better financial performance across multiple metrics, including cash flow, net profit, and return on equity. Within biotechnology specifically, she has highlighted that women-led companies have shown meaningfully better performance relative to comparable businesses under traditional management structures. Her position is that this is not a social observation. It is a data-supported argument about the value that different experiential backgrounds bring to the analytical work of evaluating scientific risk, setting development priorities, and making capital allocation decisions under uncertainty.

At Propel Bio Partners, further profiled in Kawas’s coverage at leenkawas.news, the venture firm she co-founded in 2022, governance is embedded in the investment thesis rather than treated as a post-investment concern. The firm evaluates potential portfolio companies against multiple criteria simultaneously, including financial position, management team composition, corporate development strategy, and governance structure. The majority of companies Propel has backed feature women in leadership positions. Kawas has framed this not as a social responsibility programme but as a selection mechanism: companies with diverse governance are, in her experience, more likely to surface the questions that matter and less likely to commit to a course of action that a single dominant perspective would have ratified unchallenged.

Governance and the Innovation Bottleneck

The funding environment that has shaped biotech since the peak of 2021 has placed governance under a particular kind of pressure. As venture capital investment contracted sharply from its record high, investor scrutiny of pipeline decisions, capital discipline, and clinical strategy intensified. Companies that had built their cases around platform technologies without near-term clinical proof of concept found themselves exposed. Kawas has observed that the boards best positioned to navigate that environment were the ones that had already built the capacity to ask hard questions about which programmes were serving genuine unmet needs and which were consuming resources in service of scientific ambition that exceeded the evidence base.

Her own role at EIT Pharma (see leenkawas.com), where she serves as CEO and leads programmes targeting Hepatitis D and Acute Respiratory Infections, reflects the same principle applied operationally. These are conditions with high unmet need and patient populations that have been underserved by a pharmaceutical industry that has historically prioritised conditions with larger commercial returns in wealthier markets. The governance framework Kawas applies there asks, at every stage of development, whether the decisions being made are genuinely oriented toward the patients who need the therapy. That question, asked consistently at board level, is what she believes converts governance from a constraint into a catalyst.

The Scientist on the Board

Leen Kawas serves on the boards of Inherent Biosciences, which uses AI-driven epigenetic approaches to address complex health problems, and has previously served on the Scientific Review Board for the Alzheimer’s Drug Discovery Foundation. She has described what she brings to those roles as a capacity to assess scientific opportunity by drawing on direct experience across drug discovery, clinical trial methodology, regulatory strategy, and commercialisation, combined with the financial perspective of someone who has raised and deployed substantial capital. A board that holds those perspectives together, rather than separating scientific oversight from financial governance, is, in her view, structurally better positioned to make the decisions that innovation actually requires.